XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
(%)
3)
3/4
70 11
(Grade
25.6
81
26.9
100
15.4
Toxicity:
Grade
neutropenia
38.1
(%)
— 43
Stable
18.0 25.6 44.5
—
12.5
44
disease
10
9
15 15
Survival
21.1 19.4
47 —
(months)
(%)
28 39 41 25 67 71 —
RR
64.0
(
n
)
27 44 21 39 36 26 42 13
Patients
q3w
paclitaxel
2,
q3w
q4w
3,
15;
15,
2
/day
and
1
q3w day
carboplatin
and
and
q3w
weekly;
weeks
rest
3 2
/day,
mg/m
respectively
1–3, day
1–3,
1,
on
8, 1
Dose
1–5,
1,
day
1–3; 5
1–3,
q3w 1,
once
for
week
8,
600
days
3,
days
i.v. days AUC
day
days
day
i.v.
1
mg/m
gemcitabine and
days
i.v.
2
2
i.v.
2 by
0.5 and
1 i.v.
i.v.
2
days day
i.v.
i.v.
2 2
i.v.
i.v. 2
i.v.
on 2
2
2
weekly,
1–5;
2
mg/m
mg/m
mg/m 2
5
mg/m
mg/m
mg
days
mg/m
mg/m
2006). mg/m
30
70 once followed days 800 on
mg/m
1500 600
mg/m
mg/m
mg/m
AUC carboplatin 85
1 1.75 Topotecan 1.3 1.25 1 1.5 2–4
curve.
the
Fleming,
and
under
Obel
area
PLDH paclitaxel
from
AUC:
Treatment
þ þ
gemcitabine ifosfamide cyclophosphamide
carboplatin carboplatin oxaliplatin
rate;
(Adapted
þ þ þ
þ þ þ
Topotecan Topotecan Topotecan Topotecan Topotecan Topotecan Topotecan Topotecan
response
therapy
RR:
Phase
weeks;
II II II II II I/II II I
4
combination
49
every
53
54
2007
52
q4w:
.,
50
51
topotecan al
2007
2007 55
of
48
et
2002 2002
.,
.,
.,
2004
.,
al
al
2006
al
.,
al
al
2007
weeks;
et
et
.,
3
Trials .,
et
et
et
al
et
4.
al
every
et
Study Verhaar-Langereis Stathopoulos Sehouli Chiara Hanjani Koensgen Vecchione Elkas q3w:
Table
8
Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik
www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34